Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.
about
Elotuzumab for the treatment of multiple myelomaMultiple myeloma in the very elderly patient: challenges and solutionsMonoclonal antibodies targeting CD38 in hematological malignancies and beyondMultiple myeloma and physical activity: a scoping reviewEuropean perspective on multiple myeloma treatment strategies in 2014Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesA clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myelomaNew investigational drugs with single-agent activity in multiple myelomaThe role of maintenance therapy in multiple myelomaRecent advances in multiple myeloma: a Korean perspectiveThe insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potentialSpotlight on elotuzumab in the treatment of multiple myeloma: the evidence to dateClinical use of proteasome inhibitors in the treatment of multiple myelomaCarfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factorsInhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737Integrative network modeling approaches to personalized cancer medicineCancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myelomaPrimary plasma cell leukemia 2.0: advances in biology and clinical management.The next generation of novel therapies for the management of relapsed multiple myeloma.The role of SLAMF7 in multiple myeloma: impact on therapy.Are maintenance and continuous therapies indicated for every patient with multiple myeloma?Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatmentRisk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen.A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple MyelomaTrends in survival of patients with primary plasma cell leukemia: a population-based analysis.Multiple myeloma in the older adult: better prospects, more challenges.Malignant lymphatic and hematopoietic neoplasms mortality in Serbia, 1991-2010: a joinpoint regression analysis.Clinical course and prognosis of non-secretory multiple myeloma.Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.Efficient transient transfection of human multiple myeloma cells by electroporation--an appraisal.The use of novel agents in multiple myeloma patients with hepatic impairment.Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.
P2860
Q26740278-ACED24E3-CC45-4DB7-BCD9-A502E09B1359Q26752991-5F8CB7B7-6080-4644-9EF1-6BBEF3C35507Q26766718-8CF5674D-3DB0-4305-923B-207F15A630F5Q26776341-8C217CDA-0FE6-4CD7-9279-EAE307EA9577Q27005966-5E1C0FED-C674-411F-B957-EF1DF1A9DD1AQ27026478-5036226C-E48A-41AF-8C6B-266E16DEA162Q28067148-BF109B31-4638-4E2B-8993-8B8AF0C0D7C8Q28071551-979DAE4B-AFB3-4362-88A7-F746D7E622A6Q28071644-7F5FA63F-75B6-4654-9AF2-B550E053F33AQ28074521-C5C80425-5898-47EC-BEAF-AD9D96DFA909Q28075927-5840D09B-45D7-46DF-A197-DC93AB2FEEC9Q28076147-0A59FD89-E2E7-4E25-8E38-8A2FC953B486Q28080999-5857CBDB-1881-49C9-A954-E0D8488B5683Q28084683-9EE90D67-26F9-4E2C-A421-CC019293B673Q28542684-FEB80C74-DC88-4A09-99CC-F9D3EE6710C0Q28602016-4328B171-6023-4D96-BC25-E7632B609E65Q28648164-B166D9A4-B49E-40A0-ACA0-261AE25E3A1CQ30243927-A3E44319-2AAB-4C5B-AC1C-ECFB719B126BQ30248534-184FB54C-83C8-484B-B0B5-5AC84FFB1FDCQ30249167-B45BD4CF-A9B4-4044-A727-E0D18C2F9C37Q30249790-EE2E7678-ADF7-4669-AF93-26FDFFA20195Q33423168-77C27647-0A73-4AD7-8103-F052DB7D0934Q33428098-432C89CB-6770-4593-8E04-2BC9F9F94B94Q33434435-E769D431-A894-4150-848D-D678B0F86CB0Q33436890-F6187B8C-AC0A-4EC1-9712-165ADA4B3F71Q33439437-C245322B-FAA7-424A-A2A4-95645FAEABC0Q33441702-A80F049C-5CB3-43CC-969F-FE7953AD7BB2Q33443406-4B839618-4249-4189-BA98-2B90A868D52FQ33443417-9B2AB0C4-195E-4432-B7D3-A1A4C875A0DAQ33703097-91C71CDC-3CD2-4E50-B974-FEDBBBA94BC0Q34019590-B32D4BD4-9452-49EE-8DD9-449BA4D62DCEQ34031129-AA562333-A917-4355-86A2-E7B3EA67D964Q34379476-6CE65EC3-B529-4093-9B09-6CE54B6F7009Q34447010-F24FB9D6-18D6-40A9-90CD-1D5E4502DFA2Q34798105-A2D499D4-FFB5-45D6-84BD-7D69F010FDC1Q34893956-5F5A76E9-44F8-4CDF-9792-2C3A60F8A150Q35182314-FF2E819B-8B48-49C4-A0BA-A49086B802E2Q35182819-012E6BDE-833B-4F05-8BB3-A62E29569F30Q35244883-92486973-4F86-4E45-98EC-18E197E66BE5Q35410550-2061E451-0AB0-4708-BB5E-F8AF9E3FCBCE
P2860
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Continued improvement in survi ...... nd outcomes in older patients.
@en
Continued improvement in survi ...... nd outcomes in older patients.
@nl
type
label
Continued improvement in survi ...... nd outcomes in older patients.
@en
Continued improvement in survi ...... nd outcomes in older patients.
@nl
prefLabel
Continued improvement in survi ...... nd outcomes in older patients.
@en
Continued improvement in survi ...... nd outcomes in older patients.
@nl
P2093
P2860
P50
P356
P1433
P1476
Continued improvement in survi ...... and outcomes in older patients
@en
P2093
S J Russell
P2860
P2888
P304
P356
10.1038/LEU.2013.313
P577
2013-10-25T00:00:00Z